Molokhia Sarah A, Jeong Eun-Kee, Higuchi William I, Li S Kevin
Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah 84112, USA.
J Pharm Sci. 2008 Feb;97(2):831-44. doi: 10.1002/jps.21003.
The flux enhancing mechanisms of transscleral iontophoresis are not well understood. The objective of the present study was to investigate the ocular barrier and barrier alterations in transscleral iontophoretic delivery with magnetic resonance imaging (MRI). Experiments involving constant current transscleral iontophoresis of 2 mA (current density 10 mA/cm(2)) and subconjunctival injection were conducted with rabbits in vivo and postmortem and with excised sclera in side-by-side diffusion cells in vitro. The postmortem and in vitro experiments were expected to be helpful in clarifying the importance of vascular clearance and other transport barriers in transscleral iontophoresis. Manganese ion (Mn(2+)) and manganese ethylenediaminetetraacetic acid complex (MnEDTA(2-)) were the model permeants. The results show that pretreatment of the eye with an electric field by iontophoresis enhanced subconjunctival delivery of the permeants to the anterior segment of the eye in vivo. This suggests that electric field-induced barrier alterations can be an important absorption enhancing mechanism of ocular iontophoresis. Penetration enhancement was magnified in the postmortem experiments with larger amounts of the permeants delivered into the eye and to the back of the eye. The different results observed in the in vivo and postmortem studies can be attributed to ocular clearance in ocular delivery.
经巩膜离子电渗疗法的通量增强机制尚未完全明确。本研究的目的是利用磁共振成像(MRI)研究经巩膜离子电渗给药过程中的眼部屏障及屏障改变。在兔体内、死后及体外并排扩散池中使用切除的巩膜进行了涉及2 mA(电流密度10 mA/cm²)恒流经巩膜离子电渗疗法和结膜下注射的实验。预期死后及体外实验有助于阐明经巩膜离子电渗疗法中血管清除及其他转运屏障的重要性。锰离子(Mn²⁺)和乙二胺四乙酸锰络合物(MnEDTA²⁻)为模型渗透剂。结果表明,通过离子电渗疗法用电场对眼部进行预处理可增强体内结膜下渗透剂向眼前段的递送。这表明电场诱导的屏障改变可能是眼部离子电渗疗法重要的吸收增强机制。在死后实验中,随着更多渗透剂递送至眼内及眼后,渗透增强作用被放大。体内和死后研究中观察到的不同结果可归因于眼部给药中的眼部清除作用。